nimotuzumab
Showing 1 - 25 of 69
Solid Tumor, EGFR Amplification Trial in Tianjin (Nimotuzumab)
Recruiting
- Solid Tumor
- EGFR Amplification
- Nimotuzumab
-
Tianjin, Tianjin, ChinaTianjin Medical University Second Hospital
Aug 28, 2023
Esophageal Carcinoma Trial in Nanjing (Nimotuzumab, Tigio, Concurrent radiation therapy)
Enrolling by invitation
- Esophageal Carcinoma
- Nimotuzumab
- +2 more
-
Nanjing, Jiangsu, ChinaThe First Affiliated Hospital of Nanjing Medical University
Sep 19, 2023
Nasopharyngeal Carcinoma, Nasopharyngeal Tumors, Nasopharyngeal Diseases Trial in Guangzhou (Nimotuzumab, Cisplatin)
Recruiting
- Nasopharyngeal Carcinoma
- +3 more
- Nimotuzumab
- Cisplatin
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Nov 3, 2022
Penile Cancer Trial in Guangzhou (Albumin-Bound Paclitaxel, Ifosfamide, Cisplatin)
Completed
- Penile Cancer
- Albumin-Bound Paclitaxel
- +4 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Jun 8, 2022
Nasopharyngeal Carcinoma Trial in Shanghai (Camrelizumab, Nimotuzumab, neoadjuvant chemo and CCRT)
Recruiting
- Nasopharyngeal Carcinoma
- Camrelizumab
- +2 more
-
Shanghai, Shanghai, ChinaFudan Universtiy Shanghai Cancer Centre
Mar 6, 2023
Pancreatic Neuroendocrine Tumor Trial in Shanghai (Nimotuzumab)
Not yet recruiting
- Pancreatic Neuroendocrine Neoplasm
- Nimotuzumab
-
Shanghai, Shanghai, ChinaDepartment of Pancreatic Surgery, Fudan University Shanghai Canc
Apr 4, 2022
Nasopharyngeal Carcinoma by AJCC V8 Stage Trial in China (Nimotuzumab, Gemcitabine, Cisplatin)
Recruiting
- Nasopharyngeal Carcinoma by AJCC V8 Stage
- Nimotuzumab
- +3 more
-
Baise, Guangxi, China
- +8 more
Jan 29, 2023
Esophageal Trial in China (Nimotuzumab, Radiotherapy)
Completed
- Esophageal
- Nimotuzumab
- Radiotherapy
-
Harbin, Heilongjiang, China
- +4 more
Mar 3, 2022
Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN
Recruiting
- Locally Advanced Head and Neck Squamous Cell Carcinoma
- nimotuzumab
-
Beijing, Beijing, China
- +4 more
Mar 3, 2022
Esophageal Cancer, Chemoradiotherapy, Nimotuzumab Trial in Beijing (Radiotherapy, Nimotuzumab, S-1)
Recruiting
- Esophageal Cancer
- +3 more
- Radiotherapy
- +2 more
-
Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/Nationa
Oct 21, 2021
Oral Squamous Cell Carcinoma Trial in Yichang (Nimotuzumab, Docetaxel, Carboplatin)
Recruiting
- Oral Squamous Cell Carcinoma
- Nimotuzumab
- +2 more
-
Yichang, Hubei, ChinaDepartment of Medical Oncology, Central Hospital of Yichang City
Nov 5, 2021
Cervical Squamous Cell Carcinoma Trial in Beijing (Nimotuzumab, EBRT combined with brachytherapy)
Not yet recruiting
- Cervical Squamous Cell Carcinoma
- Nimotuzumab
- EBRT combined with brachytherapy
-
Beijing, Beijing, ChinaPeking University 3rd Hospital
Jul 21, 2021
Head and Neck Squamous Cell Carcinoma Trial in China (Nimotuzumab)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- Nimotuzumab
-
Hangzhou, China
- +5 more
Aug 20, 2021
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Trial (Nimotuzumab, Sintilimab, Chemotherapy drug)
Not yet recruiting
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Nimotuzumab
- +2 more
- (no location specified)
May 6, 2021
Carcinoma, Squamous Cell of Head and Neck Trial in Worldwide (Nimotuzumab, Placebo)
Active, not recruiting
- Carcinoma, Squamous Cell of Head and Neck
- Nimotuzumab
- Placebo
-
Bedford Park, Australia
- +29 more
Apr 4, 2022
Leptomeningeal Metastasis, Lung Cancer Trial in Hebei (Nimotuzumab)
Recruiting
- Leptomeningeal Metastasis
- Lung Cancer
- Nimotuzumab
-
Hebei, Shijiazhuang/hebei, China
- +1 more
Apr 18, 2021
Esophageal Cancer Trial in Beijing (Nimotuzumab)
Completed
- Esophageal Cancer
- Nimotuzumab
-
Beijing, Beijing, ChinaCancer Hospital, Chinese Academy of Medical Sciences
Feb 2, 2021
Nasopharyngeal Carcinoma Trial in Beijin (Nimotuzumab, VMAT)
Recruiting
- Nasopharyngeal Carcinoma
- Nimotuzumab
- VMAT
-
Beijin, ChinaCancer hospital, Chinese Academy of Medical Sciences
Jan 28, 2021
NSCLC Trial in Guangzhou (Avitinib Maleate, Afatinib, Crizotinib)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Avitinib Maleate
- +13 more
-
Guangzhou, Guangdong, ChinaGuangdong Lung Cancer Institute, Guangdong Provincial People's H
Dec 3, 2022
Non-small-cell Lung Cancer Trial in Guangzhou (Nimotuzumab, docetaxel and cisplatin, daily RT to the chest)
Completed
- Non-small-cell Lung Cancer
- Nimotuzumab
- +2 more
-
Guangzhou, Guangdong, ChinaSun yat-sen University Cancer Center
Feb 8, 2021
Cervical Squamous Cell Carcinoma Trial in Beijing (Nimotuzumab, Cisplatin, External-beam radiation)
Not yet recruiting
- Cervical Squamous Cell Carcinoma
- Nimotuzumab
- +3 more
-
Beijing, Beijng, ChinaPeking University 3rd Hospital
Dec 16, 2020
Esophagus Cancer, Esophagogastric Junction Cancer, Chemoradiation Trial in China (Radiotherapy, Platinum based chemo, Paclitaxel
Recruiting
- Esophagus Cancer
- +5 more
- Radiotherapy
- +5 more
-
Anyang, Henan, China
- +4 more
Aug 17, 2022
Esophageal Cancer, Chemo Effect, Chemoradiation Trial in Beijing (drug, radiation, procedure)
Recruiting
- Esophageal Cancer
- +6 more
- Platinum based chemotherapy
- +6 more
-
Beijing, ChinaDepartment of Radiation Oncology, National Cancer Center/Nationa
Mar 26, 2021
Diffuse Intrinsic Pontine Glioma Trial in Milan (Nimotuzumab, Vinorelbine, Radiotherapy)
Recruiting
- Diffuse Intrinsic Pontine Glioma
- Nimotuzumab
- +2 more
-
Milan, ItalyFondazione IRCCS Istituto Nazionale Tumori
Sep 3, 2021